共 50 条
Acute-on-chronic liver failure in chronic hepatitis B
被引:66
|作者:
Seto, Wai-Kay
[1
]
Lai, Ching-Lung
[1
,2
]
Yuen, Man-Fung
[1
,2
]
机构:
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, State Key Lab Liver Res, Hong Kong, Hong Kong, Peoples R China
关键词:
acute-on-chronic liver failure;
hepatitis B;
hepatitis B virus DNA;
liver failure;
Model of End-stage Liver Disease;
survival;
SEVERE ACUTE EXACERBATION;
PLACEBO-CONTROLLED TRIAL;
BLOOD MONONUCLEAR-CELLS;
DISEASE SCORING SYSTEM;
HBV DNA LEVELS;
E-ANTIGEN;
LAMIVUDINE TREATMENT;
CHINESE PATIENTS;
CORE PROMOTER;
HEPATOCELLULAR-CARCINOMA;
D O I:
10.1111/j.1440-1746.2011.06971.x
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Acute-on-chronic liver failure (ACLF) in chronic hepatitis B (CHB) is most commonly caused by acute severe exacerbation of CHB. The pathophysiology of ACLF in CHB is still poorly understood. Despite the identification of important predisposing factors and prognostic markers, ACLF in CHB remains a disease associated with high mortality. The majority of studies using nucleoside analog therapy did not show any significant improvement in survival, although larger prospective studies are needed. Liver transplantation is the definitive treatment for ACLF in CHB. The challenge ahead would be prognosticating cases with favorable or unfavorable outcomes in order to streamline patients for early transplantation or for medical therapy.
引用
收藏
页码:662 / 669
页数:8
相关论文